The Netherlands
Sapreme Technologies BV, founded in 2016 and headquartered in The Netherlands, is pioneering in the biotechnology field by focusing on intracellular delivery of biologics. Their mission revolves around overcoming endosomal entrapment challenges to enhance the effectiveness of macromolecule therapeutics.
The company’s cutting-edge platform enables the targeted release of biologics into the intracellular space, significantly broadening the therapeutic window while maintaining low toxicity levels. This technology is poised to transform the drug development landscape, addressing both existing and "undruggable" targets by facilitating the escape of macromolecules from the endo-lysosomal space, without compromising the integrity of plasma membranes.
In their latest financial milestone, Sapreme Technologies BV secured a €15.00M Series A investment in October 2021, led by Aglaia Biomedical Ventures. This funding is intended to accelerate their internal pipeline and expand potential partnerships across diverse macromolecule modalities and indications.
